These data demonstrated that inhibiting VDR effectively suppressed the proliferation of CML cells independent of BCR::ABL1 mutations, avoiding the resistance of CML to TKIs. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.